Carcinogenesis Advance Access published online on September 17, 2008
Carcinogenesis, doi:10.1093/carcin/bgn219
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ligand activation of peroxisome proliferator-activated receptor-β/
(PPARβ/
) inhibits chemically-induced skin tumorigenesis
1 Department of Veterinary Science and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802
2 Integrative Biosciences Graduate Program, Huck Institutes for Life Sciences, The Pennsylvania State University, University Park, PA 16802
3 Infectious Disease Pathogenesis Section, Comparative Medicine Branch & SoBran, Inc., National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892
4 Non-Clinical Pathology Research Center, Medvill, Seoul, Korea 153-801
5 Laboratory of Metabolism, National Cancer Institute, Bethesda, Maryland 20892
* To whom correspondence should be addressed: Jeffrey M. Peters, Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, Tel: (814) 863 1387, Fax: (814) 863-1696, Email: jmp21{at}psu.edu
PPARβ/
-null mice exhibit enhanced tumorigenesis in a two-stage chemical carcinogenesis model as compared to wild-type mice. Previous work showed that ligand activation of PPARβ/
induces terminal differentiation and inhibits proliferation of primary keratinocytes, and this effect does not occur in the absence of PPARβ/
expression. In the present studies, the effect of ligand activation of PPARβ/
on skin tumorigenesis was examined using both in vivo and ex vivo skin carcinogenesis models. Inhibition of chemically-induced skin tumorigenesis was observed in wild-type mice administered GW0742, and this effect was likely the result of ligand-induced terminal differentiation and inhibition of replicative DNA synthesis. These effects were not found in similarly treated PPARβ/
-null mice. Ligand activation of PPARβ/
also inhibited cell proliferation and induced terminal differentiation in initiated/neoplastic keratinocyte cell lines representing different stages of skin carcinogenesis. These studies suggest that topical administration of PPARβ/
ligands may be useful as both a chemopreventive and/or chemotherapeutic approach to inhibit skin cancer.
Received June 6, 2008; revised September 8, 2008; accepted September 11, 2008.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. Ehrenborg and A. Krook Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor {delta} Pharmacol. Rev., September 1, 2009; 61(3): 373 - 393. [Abstract] [Full Text] [PDF] |
||||
